TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03823248
Drug: Folic Acid Tablet simulation
Normalized name: folic acid Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of folic acid simulation tablets half a hour after meal for 5 mg each time for 3 times a day.
Study: NCT00694369
Drug: Comparator: etoricoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: etoricoxib 90 mg; 120 mg (once daily) over three days.
Study: NCT00694369
Drug: Comparator: ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: ibuprofen 2400 mg (600 mg Q6h) over three Days
Study: NCT00694369
Drug: Comparator: acetaminophen + codeine
Approvals — FDA: no, EMA: no, PMDA: no
Description: acetaminophen 2400 mg/codeine 240 mg (600/60 mg Q6h) over three Days
Study: NCT00694369
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo over three Days
Study: NCT01899599
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: start dose matching 500mg at C0D1, maintenance dose matching 1700mg at CxD1, Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT04372602
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Provided by Verastem
Study: NCT01279057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray administered once daily (4 actuations) for 14 days.
Study: NCT01356381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg bid
Study: NCT03023085
Drug: BLI4700
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI4700 bowel preparation
Study: NCT03426176
Drug: ATD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration of ATD (75.2g) (Acute Tryptophan Depletion)
Study: NCT00496847
Drug: PERIOGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)
Study: NCT01709695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
Study: NCT03072485
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical diclofenac applied to the skin
Study: NCT00911261
Drug: Oxymorphone Extended Release
Normalized name: oxymorphone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets~* Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets~* Treatment will consist of up to 12 months of dosing with Oxymorphone ER.
Study: NCT00546611
Drug: PEP005
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03254186
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo is started one tablet twice per day per oral, increase over the first two weeks to reach one tablet four times per day, then will remain on this dose for six weeks.
Study: NCT02357940
Drug: Experimental Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Colloidal Oatmeal Balm
Study: NCT04122599
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin for prevent post stroke delirium
Study: NCT01611181
Drug: Hemoboost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg specially processed haemoglobin and 30 mg iron dextran equivalent to 10.5 mg organically bound iron in 1 tablet twice daily.
Study: NCT01611181
Drug: Kräuterblut
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg iron, 20 ml twice daily.
Study: NCT01611181
Drug: Ferrofumerat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ferrous sulphate as 1 tablet twice daily.
Study: NCT04174911
Drug: BOL-DP-o-08
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOL-DP-o-08 sublingual drops
Study: NCT04174911
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sublingual drops
Study: NCT04222712
Drug: TRS01 eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosed four times a day (QID)
Study: NCT03979638
Drug: BLU-5937
Normalized name: Blu-Kote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four escalating doses of BLU-5937 administered BID over the course of the study
Study: NCT03979638
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for BLU-5937
Study: NCT00483964
Drug: Bacopa monnieri
Normalized name: BACOPA MONNIERI WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00483964
Drug: Nardostachys jatamansi
Normalized name: Nardostachys chinensis root extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00578942
Drug: Campath Purged Non-myeloablative ASCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Subject Evaluation will occur 2-3 times per week by physical exam for toxicity through day 45.
Study: NCT05320991
Drug: Nacl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution will also be applied with the Graseby 3500 intravenous infusion pump controlled by the STANPUMP software (Steven Shafer, M.D., Anesthesiology Service, PAVAMC 3801 Miranda Ave., Palo Alto, USA).
Study: NCT03664752
Drug: IDP-120 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-120 Gel, once-daily application
Study: NCT03664752
Drug: IDP-120 Vehicle Gel
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-120 Vehicle Gel, once-daily application
Study: NCT03465878
Drug: LY900014
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via SC injection
Study: NCT02750059
Drug: TDF/3TC/EFV only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.
Study: NCT00267527
Drug: CJC 1295
Normalized name: CJC-1295
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00220376
Drug: SPM 907
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00133874
Drug: SB-275833 ointment, 1%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03995212
Drug: CR845 1.0 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral CR845 1.0 mg administered twice daily
Study: NCT03995212
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Placebo administered twice daily
Study: NCT00128921
Drug: VELCADE™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:~Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.~Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated.
Study: NCT00062465
Drug: TwHF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02231346
Drug: Berodual® Respimat® - inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00082433
Drug: Ixabepilone + Capecitabine
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
Study: NCT00082433
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle
Study: NCT01220271
Drug: LY2157299
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01220271
Drug: Radiation
Normalized name: Miaderm Radiation Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as approved
Study: NCT01672476
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04425746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00719836
Drug: SB1518
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
Study: NCT00343733
Drug: OraVescent Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01757119
Drug: Tardyferon 80 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration (2 tablets)
Study: NCT00016952
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00016952
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00098111
Drug: azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02180516
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02180516
Drug: Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02722447
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 6 weeks
Study: NCT01705288
Drug: intravenous narcotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: given for pain management after surgery per physician orders
Study: NCT01705288
Drug: standard anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalant or intravenous during surgery
Study: NCT01705288
Drug: regional anesthesia
Normalized name: ACL6SP45 REGIONAL ANESTHESIA KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: given by spinal or epidural infusion
Study: NCT01705288
Drug: Non-steroidal anti-inflammatory drugs
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: given for pain management after surgery
Study: NCT02145039
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
Study: NCT01064791
Drug: mycophenolic acid + tacrolimus + standard of care medications
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
Study: NCT01786629
Drug: SUPREP Bowel Prep Kit
Normalized name: Suprep Bowel Prep Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for oral administration prior to colonoscopy
Study: NCT00417794
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.
Study: NCT00232908
Drug: ARV regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00144339
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01308190
Drug: Capecitabine (Xeloda)
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
Study: NCT02972216
Drug: Nolbaxol
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04200248
Drug: RBM-007 Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBM-007 Injectable Solution
Study: NCT04200248
Drug: Sham
Normalized name: SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham intravitreal injection
Study: NCT01262885
Drug: GSK2251052
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg tablet, dose levels detailed in Arm description
Study: NCT01262885
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablet
Study: NCT02313610
Drug: Qinbudan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains three kinds of traditional Chinese medicine radix scutellariae, radix stemona, liquorice
Study: NCT02313610
Drug: Qinbudan Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qinbudan Placebo was the same as therapeutic drug in package,shape,size.
Study: NCT01582997
Drug: GSK2118436
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation with GSK2118436 may proceed until the overseas recommended phase III dose.
Study: NCT00294164
Drug: Serostim®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
Study: NCT00294164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
Study: NCT04498793
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
Study: NCT01268384
Drug: Gemcitabine plus Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d. po from D1 to D14 every 21 days
Study: NCT01241903
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients (n = 54) presenting acute coronary syndrome/non-ST elevation myocardial infarction who present within 8 hours of symptom-onset will be randomized to two groups to receive rosuvastatin (40 mg oral dose) or placebo at the time of presentation, in addition to standard of care (aspirin, clopidogrel, low molecular weight heparin). Blood will be collected at baseline (time of enrollment, immediately prior to drug or placebo), at 6 - 8 hours, at 18 - 24 hours, and at 30 days for analysis of platelet - leukocyte co-aggregate formation, biomarkers of platelet - leukocyte interactions, and biomarkers of myocardial necrosis. Additional samples may be collected just after revascularization, in patients undergoing PCI. The group of patients treated with rosuvastatin will be maintained on rosuvastatin 20 mg daily and the group randomized to placebo will be given rosuvastatin (20 mg oral once daily) within 48 hoursof enrollment and after planned PCI, but before hospital discharge.
Study: NCT01241903
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: frequency and duration
Study: NCT01516944
Drug: Oxaliplatin; Capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation
Study: NCT03329690
Drug: DS-8201a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8201a is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration.
Study: NCT03329690
Drug: Physician's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either:~Irinotecan monotherapy (Starting dosage and usage is 150 mg/m2 biweekly, with dose reduction permitted)~Paclitaxel monotherapy (Starting dosage and usage is 80 mg/m2 weekly, with dose reduction permitted)
Study: NCT02559869
Drug: [18F] GE-180
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET Tracer Ligand
Study: NCT01289769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 20 ml( the same volume as dexmedetomidine) giving within 10 minutes.
Study: NCT00006489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill Placebo daily dosing 24 weeks
Study: NCT02203487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00712465
Drug: AZD1305
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended Release tablet, repeated administration
Study: NCT01617057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg / day for 3 month
Study: NCT01250470
Drug: Montanide ISA-51/Survivin Peptide Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given SC
Study: NCT01565330
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose IV injection
Study: NCT01564303
Drug: Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine
Approvals — FDA: no, EMA: no, PMDA: no
Description: to evaluate the effect of the above agents on Kidney functioning parameters
Study: NCT00577512
Drug: DTPACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Dexamethasone 200 mg Intravenous Infusion Piggy-Back (IVPB) Days 1-7~* Thalidomide 200 mg by mouth (PO) Days 1-7~* Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)~* Adriamycin 15 mg/m2 Days 1-4~* Cyclophosphamide 600 mg/m2 Days 1-4~* Etoposide 60 mg/m2 Days 1-4
Study: NCT00500292
Drug: FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion
Study: NCT03144882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01625455
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given orally for a total of 7 days.
Study: NCT02860715
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the placebo of GX-I7 described above.
Study: NCT02653651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An equal volume of saline
Study: NCT00446147
Drug: Pyridoxine
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg BID/daily, Per oral
Study: NCT00446147
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 100mg BID/daily, Per oral
Study: NCT01644175
Drug: Placebo (for alirocumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
Study: NCT01644175
Drug: Lipid-Modifying Therapy (LMT)
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Study: NCT00864747
Drug: INDERAL® LA 160 mg Capsules, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products non-under fasting conditions
Study: NCT01747083
Drug: FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01705691
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles
Study: NCT01705691
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles
Study: NCT04045678
Drug: Placebo, extended-release microspheres
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients to be enrolled to 70 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week and then 70 mg in the next 5 weeks.~Patients to be enrolled to 84 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week,56 mg in the fourth week, 70mg in the fifth week and then 84 mg in the next 5 weeks.
Study: NCT04220411
Drug: AR100DP1
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical ointment
Study: NCT00181961
Drug: Maca Root
Normalized name: maca root
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02071524
Drug: Group Colloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)
Study: NCT04407130
Drug: Ivermectin + Doxycycline + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm I: 200 mcg/kg (12 mg tablet) ivermectin (IVERA) single dose and 200 mg stat doxycycline day-1 followed by 100mg doxycycline 12hrly for 4 day (i.e. day2-day5)~Placebo one tablet D2-5
Study: NCT04407130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm III: 3 Placebo tablets D1 followed by 2 tablets D2-5
Study: NCT00006481
Drug: Biafine cream
Normalized name: BIAFINE CREAM,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02653742
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac 1mg/kg sublingual is administered after induction of general anesthesia.
Study: NCT02653742
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 2mg/kg intranasal is administered after induction of general anesthesia
Study: NCT03738943
Drug: Acetylcholine
Normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm/group descriptions
Study: NCT03738943
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: See arm/group descriptions
Study: NCT03738943
Drug: Vitamin B 6
Normalized name: vitamin B 6 100 MG/ML Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm/group descriptions
Study: NCT04347382
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empty capsule with 250ml of distilled water
Study: NCT00748215
Drug: calcium aluminosilicate anti-diarrheal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00962104
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken by mouth, once daily for 10 weeks.
Study: NCT04056195
Drug: SKI-O-703
Approvals — FDA: no, EMA: no, PMDA: no
Description: The SKI-O-703 capsules will contain 100 mg of drug substance.
Study: NCT04056195
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules are filled with microcrystalline cellulose.
Study: NCT05175066
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets with similar shape and size and color to bisoprolol were given to the patients whom undergone chemotherapy with anthracyclines to compare the effects between two groups.